01.15.2019 Issue 434

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Report: Biotech Mulls Installments
for High-Cost Drugs

Friday, January 11

One biotech is proposing incremental payments for its experimental gene therapy, a drug expected to carry a roughly seven-figure price tag.

J&J Raises Prices after CEO Tells Pharma to Watch Price Hikes

HealthEconomics.Com Founder Talks HEOR, RWE in Publication Planning

ICER Outlines Planned Review of DMD Treatments

Innovative Drugs: Mapping the Pricing and Reimbursement Landscape


Senior Consultant/Consultant

Summer 2019 Internship - Medical Communications

Summer 2019 Internship - Health Economics and Outcomes Research

Summer 2019 Internship - Real World Evidence

Industry Spotlight


Conferences Webinars
Reimbursement and Contracting
    January 23-24, Philadelphia, Pennsylvania

Data Analytics and Decisions
    January 23-24, Philadelphia, Pennsylvania

Special Therapies 2019
    January 24-25, Las Vegas, Nevada

The Payer and Provider Ecosystem Evolution
    January 27-30, San Diego, California

How to Leverage Real World Data to Achieve Faster Insights for Better Adverse Event Detection and Reporting
    January 16

AI and the Augmented Age in Health Care
    January 23

Prove it with PROs?
    January 24

HEOR & RWE: Global Sourcing Strategies and Best Practices
    January 24


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)

From Patent to Patient: Analyzing Access to Innovative Cancer Drugs

Transitioning Payment Models: Fee-for-Service to Value-Based Care

How Health Plans and Providers Can Collaborate to Improve Care Transitions and Reduce Hospital Readmissions


 
Special Thanks to Our Partners:
               Evidera   HealthCore  
      University of FL   Xcenda  OM1    Parexel   Jefferson
      Dymaxium   Precision Xtract    Pharmerit    eMax Health
      Sciformix   Evidence Partners    ICON    Truven
Share this newsletter on social media:

Email Twitter Facebook LinkedIn